Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge.

Ronen ArbelYael Wolff SagyMoshe HoshenErez BattatGil LavieRuslan SergienkoMichael FrigerJacob G WaxmanNoa DaganRan BalicerYatir Ben-ShlomoAlon PeretzShlomit YaronDanielle SerbyAriel HammermanDoron Netzer

Published in: The New England journal of medicine (2022)

Among patients 65 years of age or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir than among those who did not. No evidence of benefit was found in younger adults.

Keyphrases

coronavirus disease
sars cov
physical activity
respiratory syndrome coronavirus
early onset
community dwelling
metabolic syndrome
skeletal muscle